Vickers Vantage Corp. I (VCKA): history, ownership, mission, how it works & makes money

Born as a blank check vehicle in 2020, Vickers Vantage Corp. I (trading as VCKA on Nasdaq) pivoted from SPAC sponsor to biotech operator when it closed a deal on November 10, 2022 to acquire Scilex Holding Company-a transaction that followed a December 2021 letter of intent valuing Scilex at about $1.5 billion and was structured to provide up to $140 million in gross proceeds to fund development and commercialization; today VCKA backs Scilex's FDA‑approved topical analgesic ZTlido® (lidocaine topical system 1.8%) and pipeline candidate SP‑102 (10 mg injectable dexamethasone for lumbosacral radicular pain), positioning the company in the rapidly growing non‑opioid pain management market while operating publicly and pursuing milestone, royalty and product sales revenue streams as of December 2025.

Vickers Vantage Corp. I (VCKA): Intro

• In December 2021 VCKA signed a letter of intent for a proposed business combination with Scilex Holding Company (a Sorrento Therapeutics, Inc. subsidiary), valuing Scilex at approximately $1.5 billion.
• The business combination was completed on November 10, 2022; following the closing VCKA's shares began trading under the ticker VCKA on the Nasdaq Capital Market.
• In April 2022 VCKA extended its SPAC combination deadline by three months to July 11, 2022 to allow additional time to close the transaction.
• As of December 2025 VCKA remains publicly traded and operates primarily through Scilex Holding Company, focusing on development and commercialization of non‑opioid pain management products.

• VCKA (post‑merger) is the publicly listed parent entity; operational assets and commercial products are held and managed through Scilex Holding Company.
• Scilex was historically affiliated with Sorrento Therapeutics prior to the transfer of assets into the VCKA combination; ownership percentages post‑closing reflect the negotiated share exchange between SPAC public shareholders, sponsors, and Scilex pre‑transaction holders.

• Mission: develop and commercialize safer, non‑opioid options for acute and chronic pain with the goal of capturing prescriber and patient demand for alternatives to opioid analgesics.
• Strategy: leverage marketed products and late‑stage assets to generate revenue while advancing pipeline candidates through clinical development and regulatory approvals.

• Commercial operations: sell prescription non‑opioid pain products through a field/specialty sales force, distributors, and wholesalers; support with marketing and medical affairs.
• R&D operations: fund clinical trials, regulatory submissions, and post‑market studies for pipeline products and label expansions.
• Corporate functions: manage investor relations, regulatory compliance, and licensing/collaboration negotiations to extend product reach.

• Product sales: revenue from marketed non‑opioid pain products (commercial sales, net of discounts and returns).
• Licensing and collaboration revenue: milestone and royalty income from third‑party partnerships or distribution agreements.
• Potential future revenue streams: government or private payer reimbursements, expanded indications, and new product launches following regulatory approvals.

Vickers Vantage Corp. I (VCKA): History

• Blank-check origins: formed as a SPAC with intent to acquire an operating business.
• Merger closed: November 2022 - business combination with Scilex Holding Company.
• Post-merger status: Scilex operates as VCKA's primary operating subsidiary.
• Trading venue: Nasdaq Capital Market, ticker VCKA.

• Primary operating subsidiary: Scilex Holding Company (a Scilex entity).
• Parent affiliation: Scilex is a subsidiary of Sorrento Therapeutics, Inc., a biopharmaceutical company focused on non-opioid pain management.
• Transaction financing: the merger was structured to provide up to $140 million in gross proceeds to support development and commercialization of Scilex's product portfolio.
• Shareholder composition (as of December 2025): mix of public shareholders plus positions held implicitly via Scilex/Sorrento-related entities; Scilex remains the primary operating subsidiary.

Vickers Vantage Corp. I (VCKA): Ownership Structure

• IPO and trust proceeds: launched Jan 2021; SPAC trust financing raised approximately $250 million to pursue a target combination.
• Business combination: merged with Scilex Holding Company to acquire a commercial-stage non-opioid pain platform backed by marketed products and late-stage pipeline assets.
• Strategic emphasis: integrates Scilex's product portfolio (topical/non-opioid analgesics) to meet rising demand for opioid alternatives.
• Governance & compliance: maintains SEC-reporting status post-combination and adheres to federal regulatory standards for drug development and commercialization.

• Revenue & commercial metrics (post-merger period, illustrative approximate figures): Scilex's commercial products contributed recurring revenue in the tens of millions annually post-transaction; management targeted accelerated commercialization and expanded payer coverage.
• Value creation drivers:
  • Commercial product sales growth and formulary uptake.
  • Launch of additional non-opioid therapies from pipeline assets.
  • Cost-effective marketing and distribution partnerships to scale sales.
• Financial positioning: Combined balance sheet typically reflected cash from SPAC trust plus PIPE proceeds to fund commercialization, R&D and regulatory activities; leverage and burn rates depend on commercialization throughput and reimbursement wins.

Vickers Vantage Corp. I (VCKA): Mission and Values

• Corporate structure: VCKA is the publicly traded parent; Scilex Holding Company is the operating subsidiary that develops and commercializes non‑opioid analgesics and related products.
• M&A strategy: The company targets acquisitions and business combinations to acquire marketed products, late‑stage candidates, or technology platforms - exemplified by its merger with Scilex in November 2022.
• Commercial focus: Scilex's marketed product portfolio centers on prescription topical analgesics designed to reduce systemic opioid exposure for acute and chronic pain indications.
• Partnerships & capabilities: VCKA leverages strategic alliances with contract manufacturers, distribution partners, clinical CROs, and R&D collaborators to accelerate product development, scale commercialization, and extend market access.
• Regulatory & compliance: Operations emphasize regulatory compliance (FDA pathways, manufacturing controls, pharmacovigilance) and investor transparency to maintain stakeholder trust.
• Patient outcomes: The core operational objective is to advance non‑opioid options that improve pain control, minimize systemic opioid risks, and support broader public‑health efforts to reduce opioid dependence.

• Commercial sales: Revenue primarily derives from sales of marketed non‑opioid analgesic products (Branded topical prescription products marketed by Scilex).
• Licensing & partnerships: Income streams include licensing fees, milestone payments, and co‑promotion or distribution agreements with larger pharmaceutical companies and specialty distributors.
• Product lifecycle management: Incremental revenue is targeted via label expansions, new dosage forms, and geographic market entries to extend product lifespan and market penetration.
• Cost structure: Major cost drivers include R&D (clinical trials for new indications), COGS (manufacture of topical products), SG&A (sales force and marketing), and regulatory/compliance expenses.

• Commercial execution: Growing prescriptions and formulary placements of marketed products drive near‑term revenue growth.
• Pipeline progression: Advancing clinical programs and label expansions can materially expand addressable markets and long‑term revenue potential.
• Partnership economics: Strategic licensing and distribution deals reduce capital intensity and accelerate market reach while providing upfront or milestone‑based cash inflows.
• Cost management: Efficient manufacturing and targeted SG&A investments improve margins as revenue scales.

• Public company reporting: Regular SEC filings and public disclosures provide financial transparency and regulatory compliance to investors.
• Board and management oversight: Corporate governance focuses on aligning incentives toward patient outcomes, commercial execution, and shareholder value creation.
• Ethics and safety: Commitment to pharmacovigilance, manufacturing quality, and ethical commercialization practices to uphold patient safety and regulatory standards.

Vickers Vantage Corp. I (VCKA): How It Works

• Primary commercial product: ZTlido® (lidocaine topical system) 1.8% - an FDA-approved topical lidocaine system indicated for relief of pain associated with postherpetic neuralgia (PHN), marketed by Scilex.
• Pipeline assets: development and potential commercialization of additional pain-management candidates such as SP-102 (an injectable dexamethasone formulation targeting lumbosacral radicular pain / sciatica).
• Partnering/licensing: potential milestone payments, royalties, and co-promotion or distribution agreements to extend market reach and monetize assets outside Scilex's direct commercial footprint.

• Net product sales - recurring revenue from prescriptions and sales of ZTlido® through retail, specialty pharmacies, and direct channels.
• Milestone and royalty income - contingent receipts from licensing agreements, regulatory approvals, and commercial milestones for pipeline products.
• Service and collaboration fees - payments from strategic collaborations, co-promotion deals, or manufacturing arrangements.

• Shingles and PHN prevalence in the U.S.: approximately 1 million new herpes zoster (shingles) cases annually; PHN occurs in roughly 10-20% of cases, creating a sizeable addressable population for topical analgesics.
• Non-opioid pain management trend: growing clinical and regulatory emphasis on opioid alternatives supports long-term demand for topical and injectable non-opioid therapies.
• Competitive landscape: topical lidocaine systems, corticosteroid injectables, and interventional pain modalities-products compete on efficacy, safety, duration of pain relief, and payer coverage.

• Volume growth of ZTlido® through increased prescriber awareness, payer access, and broadened distribution channels.
• Pipeline advancement (e.g., SP-102) to unlock milestone payments and expand product portfolio value.
• Strategic partnerships and out-licensing to capture royalties and de-risk commercialization costs.
• Cost management and scale efficiencies to improve gross margins on product sales and sustain profitability.

• Monthly/quarterly net product sales and year-over-year growth for ZTlido®.
• Gross margin on product revenue (impacted by pricing, rebates, and COGS).
• Cash runway and burn rate relative to expected milestone inflows or partnership receipts.
• Pipeline progression milestones (clinical readouts, regulatory filings) that trigger contingent revenue.

Vickers Vantage Corp. I (VCKA): How It Makes Money

• Primary commercial product: ZTlido® (1.8% lidocaine topical system) - FDA approved in 2018; marketed for post‑herpetic neuralgia and other localized neuropathic pain.
• Late‑stage pipeline asset: SP‑102 - an investigational non‑opioid formulation intended for postsurgical pain (development and regulatory milestones can trigger payments and create future sales).
• Revenue sources include product sales, collaboration/milestone payments, licensing/royalty income, and potential milestone receipts from partnerships for development or commercialization.

• Non‑opioid pain management market tailwinds: rising demand for alternatives to opioids, regulatory pressure to limit opioid prescribing, and payer interest in safer analgesics.
• Strategic position after merger: VCKA completed a business combination with Scilex in November 2022, consolidating commercial capabilities and R&D into a public vehicle focused on non‑opioid analgesics.
• Addressable market scale: global pain management markets are large - estimates commonly place the broader pain market in the tens of billions of dollars annually, with non‑opioid segments growing faster due to shifting clinical practice and regulatory scrutiny.

• Merger date: November 2022 - structural consolidation into VCKA's public corporate platform.
• Commercial traction: ZTlido® has been marketed since its approval (2018) and represents the primary revenue driver in the near term.
• Pipeline advancement: SP‑102 is a key value catalyst - successful late‑stage clinical results or regulatory approval would materially expand addressable indications and revenue potential.

• Expand product portfolio through internal development (SP‑102) and in‑licensing targeted non‑opioid analgesics.
• Geographic expansion and formulary access to increase penetration and reimbursement for ZTlido® and future products.
• Partnering for commercialization and co‑development to accelerate market entry and share development risk.
• Focus on patient‑centric delivery and safety profiles to align with payer and prescriber demand for opioid alternatives.